Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
No Thumbnail
Authors
Ivanović, VesnaDemajo, Miroslav
Krtolica-Žikić, Koviljka
Krajnović, Milena M.
Dimitrijević, Bogomir B.
Konstantinovic, M.
Baltić, Vladimir
Prtenjak, Gordana
Stojiljković, Bratislav
Breberina, Milan
Nešković-Konstantinović, Zora
Nikolić-Vukosavljević, Dragica
Contribution To Periodical
Metadata
Show full item recordAbstract
Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year sur...vival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
Keywords:
plasma TGF-beta(1) / breast cancer prognosis / survivalSource:
Clinica Chimica Acta, 2006, 371, 1-2, 191-193
DOI: 10.1016/j.cca.2006.02.027
ISSN: 0009-8981
PubMed: 16650397
WoS: 000240282600030
Scopus: 2-s2.0-33746701947
Collections
Institution/Community
VinčaTY - JOUR AU - Ivanović, Vesna AU - Demajo, Miroslav AU - Krtolica-Žikić, Koviljka AU - Krajnović, Milena M. AU - Dimitrijević, Bogomir B. AU - Konstantinovic, M. AU - Baltić, Vladimir AU - Prtenjak, Gordana AU - Stojiljković, Bratislav AU - Breberina, Milan AU - Nešković-Konstantinović, Zora AU - Nikolić-Vukosavljević, Dragica PY - 2006 UR - https://vinar.vin.bg.ac.rs/handle/123456789/3079 AB - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved. T2 - Clinica Chimica Acta T1 - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients VL - 371 IS - 1-2 SP - 191 EP - 193 DO - 10.1016/j.cca.2006.02.027 ER -
@article{ author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltić, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica", year = "2006", abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.", journal = "Clinica Chimica Acta", title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients", volume = "371", number = "1-2", pages = "191-193", doi = "10.1016/j.cca.2006.02.027" }
Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193. https://doi.org/10.1016/j.cca.2006.02.027
Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltić V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193. doi:10.1016/j.cca.2006.02.027 .
Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltić, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193, https://doi.org/10.1016/j.cca.2006.02.027 . .